[go: up one dir, main page]

NI200900037A - Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica. - Google Patents

Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica.

Info

Publication number
NI200900037A
NI200900037A NI200900037A NI200900037A NI200900037A NI 200900037 A NI200900037 A NI 200900037A NI 200900037 A NI200900037 A NI 200900037A NI 200900037 A NI200900037 A NI 200900037A NI 200900037 A NI200900037 A NI 200900037A
Authority
NI
Nicaragua
Prior art keywords
optionally substituted
derivatives
cycloalkyl
phenyl
group
Prior art date
Application number
NI200900037A
Other languages
English (en)
Inventor
Almario García Antonio
Lardenois Patrick
Olivier Anne
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NI200900037A publication Critical patent/NI200900037A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a los derivados de fórmula ganeral (I), en la que: R1 representa: un grupo fenilo o grupo naftilo, pudiendo estar estos dos grupos opcionalmente sustituidos; R2, R3 representan, independientemente el uno del otro, un átomo de hidrógeno, un grupo alquilo(C1-C6), cicloalquilo (C3-C7), cicloalquil (C3-C7) alquileno (C1-C3), opcionalmente sustituido; un grupo arilo opcionalmente sustituido; R4 representa: un átomo de hidrógeno, un grupo alquilo (C1-C6), cicloalquilo (C3-C7) o cicloalquil (C3-C7) alquileno(C1-C3), opcionalmente sustituido; un grupo arilo opcionalmente sustituido con uno o varios sustituyentes en estado de base o de sal de adición a un ácido.
NI200900037A 2006-09-22 2009-03-19 Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica. NI200900037A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0608350A FR2906250B1 (fr) 2006-09-22 2006-09-22 Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
NI200900037A true NI200900037A (es) 2014-02-20

Family

ID=37841968

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200900037A NI200900037A (es) 2006-09-22 2009-03-19 Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica.

Country Status (43)

Country Link
US (1) US7915284B2 (es)
EP (1) EP2069342B1 (es)
JP (1) JP5336378B2 (es)
KR (1) KR101470039B1 (es)
CN (1) CN101516881B (es)
AR (1) AR062897A1 (es)
AT (1) ATE467633T1 (es)
AU (1) AU2007298856B2 (es)
BR (1) BRPI0718517A2 (es)
CA (1) CA2662848C (es)
CL (1) CL2007002733A1 (es)
CO (1) CO6160308A2 (es)
CR (1) CR10643A (es)
CY (1) CY1110232T1 (es)
DE (1) DE602007006525D1 (es)
DK (1) DK2069342T3 (es)
EA (1) EA017442B1 (es)
ES (1) ES2345016T3 (es)
FR (1) FR2906250B1 (es)
GT (1) GT200900049A (es)
HN (1) HN2009000502A (es)
HR (1) HRP20100408T1 (es)
IL (1) IL197352A (es)
JO (1) JO2643B1 (es)
MA (1) MA30792B1 (es)
ME (1) ME00615B (es)
MX (1) MX2009002802A (es)
MY (1) MY145603A (es)
NI (1) NI200900037A (es)
NO (1) NO20091562L (es)
NZ (1) NZ575337A (es)
PE (1) PE20080671A1 (es)
PL (1) PL2069342T3 (es)
PT (1) PT2069342E (es)
RS (1) RS51412B (es)
SI (1) SI2069342T1 (es)
SV (1) SV2009003193A (es)
TN (1) TN2009000081A1 (es)
TW (1) TWI381837B (es)
UA (1) UA95976C2 (es)
UY (1) UY30603A1 (es)
WO (1) WO2008034974A1 (es)
ZA (1) ZA200901551B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2928922B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
FR2928924B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
FR2928921B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique
FR2933609B1 (fr) * 2008-07-10 2010-08-27 Fournier Lab Sa Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
FR2950345B1 (fr) * 2009-09-18 2011-09-23 Sanofi Aventis Derives acetyleniques de 5-phenyl-pyrazolopyridine, leur preparation et leur application en therapeutique
FR2950344B1 (fr) * 2009-09-18 2011-11-25 Sanofi Aventis Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique.
FR2953520B1 (fr) * 2009-12-04 2011-11-25 Sanofi Aventis Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
JP6007339B2 (ja) * 2012-11-29 2016-10-12 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft イミダゾピリジン誘導体
TWI644899B (zh) 2013-02-04 2018-12-21 健生藥品公司 Flap調節劑
EP3070085B1 (en) 2013-02-04 2019-01-09 Janssen Pharmaceutica NV Flap modulators
DK3027615T3 (da) * 2013-08-02 2021-10-25 Pasteur Institut Korea Antiinfektionsforbindelser
KR20170137165A (ko) 2015-04-10 2017-12-12 베이진 엘티디 인돌아민 및/또는 트립토판 2,3-디옥시게나아제로서 신규한 5 또는 8-치환된 이미다조[1,5-a]피리딘
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060680T2 (hu) 2015-11-19 2023-04-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
EP3394033B1 (en) 2015-12-22 2020-11-25 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
MD3472167T2 (ro) 2016-06-20 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
CN109952300B (zh) 2016-09-24 2022-01-18 百济神州有限公司 5或8-取代的咪唑并[1,5-a]吡啶
PE20200005A1 (es) 2016-12-22 2020-01-06 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
MA47123A (fr) 2016-12-22 2021-03-17 Incyte Corp Dérivés de benzooxazole en tant qu'mmunomodulateurs
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
CN111386114A (zh) 2017-11-25 2020-07-07 百济神州有限公司 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑
PL4212529T3 (pl) 2018-03-30 2025-07-07 Incyte Corporation Związki heterocykliczne jako immunomodulatory
HRP20230306T1 (hr) 2018-05-11 2023-05-12 Incyte Corporation Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrimido[3,2–D]pyrimidine compounds as immunomodulators
CR20220237A (es) 2019-11-11 2022-08-05 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
KR20220100921A (ko) * 2019-11-13 2022-07-18 아프리노이아 테라퓨틱스 리미티드 타우 단백질 응집체를 분해하기 위한 화합물 및 이의 용도
AR124001A1 (es) 2020-11-06 2023-02-01 Incyte Corp Proceso para fabricar un inhibidor pd-1 / pd-l1 y sales y formas cristalinas del mismo
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4041624B2 (ja) * 1999-07-21 2008-01-30 三井化学株式会社 有機電界発光素子
WO2001074813A2 (en) * 2000-03-31 2001-10-11 Ortho Mcneil Pharmaceutical, Inc. METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS
GB0119911D0 (en) * 2001-08-15 2001-10-10 Novartis Ag Organic Compounds
CA2499639C (en) * 2002-09-19 2011-11-08 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
EP1745045A4 (en) * 2004-03-08 2009-07-22 Univ North Carolina NEW DIKATIONIC IMIDAZO [1,2-A] PYRIDINES AND 5,6,7,8-TETRAHYDROIMIDAZO [1,2-A] PYRIDINES AS AGENTS AGAINST PROTOZOES

Also Published As

Publication number Publication date
EP2069342B1 (fr) 2010-05-12
HK1135388A1 (en) 2010-06-04
BRPI0718517A2 (pt) 2013-11-19
EP2069342A1 (fr) 2009-06-17
JP2010504309A (ja) 2010-02-12
PE20080671A1 (es) 2008-07-14
UA95976C2 (en) 2011-09-26
KR20090054449A (ko) 2009-05-29
TN2009000081A1 (en) 2010-08-19
UY30603A1 (es) 2008-05-02
ZA200901551B (en) 2010-06-30
CL2007002733A1 (es) 2008-04-11
DK2069342T3 (da) 2010-08-23
MEP10709A (en) 2011-12-20
SI2069342T1 (sl) 2010-09-30
CA2662848C (fr) 2014-12-23
MX2009002802A (es) 2009-04-01
CO6160308A2 (es) 2010-05-20
ATE467633T1 (de) 2010-05-15
CA2662848A1 (fr) 2008-03-27
PL2069342T3 (pl) 2010-10-29
HRP20100408T1 (hr) 2010-09-30
MA30792B1 (fr) 2009-10-01
HN2009000502A (es) 2011-07-11
GT200900049A (es) 2010-03-04
ES2345016T3 (es) 2010-09-13
MY145603A (en) 2012-03-15
FR2906250B1 (fr) 2008-10-31
CR10643A (es) 2009-04-29
AR062897A1 (es) 2008-12-10
EA200970311A1 (ru) 2009-08-28
AU2007298856B2 (en) 2012-08-09
JO2643B1 (en) 2012-06-17
IL197352A0 (en) 2009-12-24
IL197352A (en) 2014-11-30
TW200833329A (en) 2008-08-16
EA017442B1 (ru) 2012-12-28
FR2906250A1 (fr) 2008-03-28
KR101470039B1 (ko) 2014-12-05
NO20091562L (no) 2009-04-20
US20090253735A1 (en) 2009-10-08
CN101516881A (zh) 2009-08-26
TWI381837B (zh) 2013-01-11
CN101516881B (zh) 2012-07-18
JP5336378B2 (ja) 2013-11-06
PT2069342E (pt) 2010-07-19
NZ575337A (en) 2011-12-22
DE602007006525D1 (de) 2010-06-24
US7915284B2 (en) 2011-03-29
ME00615B (me) 2011-12-20
WO2008034974A1 (fr) 2008-03-27
AU2007298856A1 (en) 2008-03-27
CY1110232T1 (el) 2015-01-14
RS51412B (sr) 2011-02-28
SV2009003193A (es) 2010-02-01

Similar Documents

Publication Publication Date Title
NI200900037A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica.
CO6290657A2 (es) Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica
CO6300865A2 (es) Derivados polisustituidos de 2 aril-6-fenil-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica
DOP2010000213A (es) Derivados de carboxamidas azabiciclicas, su preparacion y su aplicacion en terapeutica
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR066107A1 (es) Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica como inhibidores de la enzimamonoacil glicerol lipasa y composiciones qu los contienen.
BRPI1007456A2 (pt) derivados de azaespiranil-alquilcarbamatos de compostos heterocíclicos com 5 membros, o respectivo preparo e a respectiva aplicação em terapêutica
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR066605A1 (es) Derivados de heteroarilamida pirimidona
UY32801A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO6251235A2 (es) Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
CO6150147A2 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
CO6150157A2 (es) Derivados de 7-alquinil-1,8- naftiridonas su preparacion y su aplicacion en terapeutica
AR072226A1 (es) Derivados triciclicos sustituidos, proceso e intermediario para su sintesis y su uso en medicamentos para el tratamiento de enfermedades mediadas por la actividad de gsk3beta.
HN2009000504A (es) Derivados de pirrolizina, indolizina y quinolizina su preparacion y su aplicacion en terapeutica.
ECSP12011671A (es) Octasacáridos n-acilos activadores de los receptores de los fgf, su preparación y su aplicación en terapéutica
CO6321242A2 (es) Compuestos de n-fenil-imidazo[1,2-alfa]piridin-2-carboxamidas su preparacion y su aplicacion en terapeutica
NI200900157A (es) Derivados de azabicicloalcano, su preparación y su aplicación en terapéutica.
CR11566A (es) Nuevos derivados cromenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO6331311A2 (es) Derivados de n-heterociclico-6-heterociclico-imidazo[1,2-alfa]piriidina-2-carboxamidas su preparacion y su aplicacion en terapeutica
AR061519A1 (es) Derivados de fenilpentadienoilo y composicion farmaceutica
CU20120041A7 (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR064747A1 (es) Derivados de triazabenzo[(alfa)]nafto[2,1,8-cde]azuleno su porcedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR066844A1 (es) Derivados de 1-bencilpirazol, su preparacion y su aplicacion en terapeutica